GLP-1/FGF21 Peptide (Novo Nordisk)

N/A

Report date: 2026/04/09 20:00:21
NME

Base Information

Drug NameGLP-1/FGF21 Peptide (Novo Nordisk)
Drug Alias NameN/A
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsFibroblast growth factor 21 agonists
TargetsGlucagon-like peptide 1 receptorFibroblast growth factor 21
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesNovo Nordisk A/S
Inactive CompaniesN/A
Active IndicationsObesityDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A